A stack is two or more compounds chosen to work together. Good stacks aren’t just “more is more” — they pair compounds whose mechanisms complement each other without doubling up on overlapping targets. Here’s the methodology that decided GLOW, KLOW, and Wolverine.

Why stack at all?

Single compounds have single mechanisms. Stacks let you address multiple pathways at once — and often the effects are multiplicative, not just additive. Three reasons researchers stack:

• Complementary mechanisms. BPC-157 promotes tissue repair via angiogenesis; TB-500 promotes actin upregulation and cell migration. Different mechanisms, same goal — combined recovery is greater than either alone.
• Pathway synergy. GHRH peptides (CJC-1295) raise GH baseline; GHRPs (Ipamorelin) trigger GH pulses. Both used together produce more GH release than either at higher dose.
• Sequential signalling. Some compounds prime, others act. KPV (an anti-inflammatory) clears the local environment so other compounds can work.

The three principles of stack design

1. Different mechanisms, same goal

The best stacks pair compounds that approach the same outcome from different angles. Doubling up on identical mechanisms wastes vial.

2. Compatible delivery and dosing

If two compounds need wildly different reconstitution, storage, or dosing frequency, they’re a pain to run together. Practical stacks share routes (all subQ, or all intranasal), tolerate the same BAC water timeline, and don’t conflict on cycle length.

3. Single change at a time

When testing a new compound, run it alone for at least one cycle. Add a second compound only after you’ve established a baseline. Otherwise you can’t tell which compound is producing which effect — or, worse, which is producing a side effect.

Case studies: GLOW, KLOW, Wolverine

Wolverine — BPC-157 + TB-500

The original recovery stack. BPC-157 covers angiogenesis and gut-axis repair; TB-500 covers actin-based cell migration and connective tissue. Together they’re studied for tendon repair, soft-tissue recovery, and post-injury research models. Both peptides are subQ injection, both well-tolerated, both share the standard 28-day BAC water shelf-life window. The compatibility makes the stack easy to run.

GLOW — BPC-157 + TB-500 + GHK-Cu

Wolverine plus GHK-Cu, a copper tripeptide studied for skin regeneration, hair follicle activation, and downstream collagen synthesis. The addition makes GLOW the go-to research stack for skin-focused protocols — adds a dermatological dimension to the recovery base without overlapping mechanisms.

KLOW — BPC-157 + TB-500 + GHK-Cu + KPV

GLOW plus KPV, an anti-inflammatory tripeptide. KPV calms the immune response in inflamed tissues, letting the regenerative effects of the other three express more cleanly. KLOW is the most aggressive of the three stacks and the one with the most research interest for chronic inflammatory research models.

Designing your own stack

1. Define the goal. Recovery? Growth? Skin? Sleep? Stack design starts with a single research question.
2. List candidate compounds. Pull from our peptide library the compounds studied for that goal. Read each compound’s “About” section for mechanism.
3. Pair on different mechanisms. Two compounds working the same pathway is a waste. Two compounds working complementary pathways toward the same goal is the whole point.
4. Check practical compatibility. Same route of administration? Same dosing frequency? Same storage requirements? If not, the stack is logistically painful.
5. Sketch a 4–8 week cycle using the Cycle & Protocol Planner — it’ll show you the combined pharmacokinetics and flag any frequency mismatches.
6. Start one compound at a time. Introduce the second after 1–2 weeks of baseline data on the first.

Stacks to avoid